Current Status of PD-1/PD-L1 Anti-tumor Therapy and Exploration of the Mechanism of Immune-related Adverse Events
Programmed cell death protein-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors are a group of immune checkpoint inhibitors. Since May 2006, there have been 10 immune checkpoint inhibitors targeting PD-1 and PD-L1 for tumor treatment. Although PD-1/PD-L1 inhibitors show promising curative ef...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese General Practice Publishing House Co., Ltd
2022-04-01
|
| Series: | Zhongguo quanke yixue |
| Subjects: | |
| Online Access: | https://www.chinagp.net/fileup/1007-9572/PDF/yx202101312.pdf |
| _version_ | 1811153559641653248 |
|---|---|
| author | YANG Leiyi, LIN Sang, XIE Qibing, YIN Geng |
| author_facet | YANG Leiyi, LIN Sang, XIE Qibing, YIN Geng |
| author_sort | YANG Leiyi, LIN Sang, XIE Qibing, YIN Geng |
| collection | DOAJ |
| description | Programmed cell death protein-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors are a group of immune checkpoint inhibitors. Since May 2006, there have been 10 immune checkpoint inhibitors targeting PD-1 and PD-L1 for tumor treatment. Although PD-1/PD-L1 inhibitors show promising curative effects on certain tumors, serious immune-related adverse events limited the clinical application. Therefore, it is urgent to develop new drugs with the same efficacy but fewer side effects than PD-1/PD-L1 inhibitors. In addition, exploring the mechanisms of immune-related adverse events provides a scientific foundation for developing personalized intervention strategies, which is equally important in the research of PD-1/PD-L1 inhibitors. This review discusses the mechanism and immune-related adverse events of several anti-PD-1/PD-L1 monoclonal antibodies, aiming at reminding clinicians of the occurrence of related adverse events while performing anti-tumor therapy. Moreover, this review also points out the possible research direction of PD-1/PD-L1 inhibitors in the future. |
| first_indexed | 2024-04-24T11:59:03Z |
| format | Article |
| id | doaj.art-c6bd63ccdba647bbab4c1a06c128c22f |
| institution | Directory Open Access Journal |
| issn | 1007-9572 |
| language | zho |
| last_indexed | 2024-04-24T11:59:03Z |
| publishDate | 2022-04-01 |
| publisher | Chinese General Practice Publishing House Co., Ltd |
| record_format | Article |
| series | Zhongguo quanke yixue |
| spelling | doaj.art-c6bd63ccdba647bbab4c1a06c128c22f2024-04-09T03:10:24ZzhoChinese General Practice Publishing House Co., LtdZhongguo quanke yixue1007-95722022-04-0125111393139810.12114/j.issn.1007-9572.2021.01.312Current Status of PD-1/PD-L1 Anti-tumor Therapy and Exploration of the Mechanism of Immune-related Adverse EventsYANG Leiyi, LIN Sang, XIE Qibing, YIN Geng0 Department of Rheumatology and Immunology，West China Hospital，Sichuan University，Chengdu 610041，China * Corresponding author：YIN Geng，Chief physician；E-mail：yingeng1975@163.com Programmed cell death protein-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors are a group of immune checkpoint inhibitors. Since May 2006, there have been 10 immune checkpoint inhibitors targeting PD-1 and PD-L1 for tumor treatment. Although PD-1/PD-L1 inhibitors show promising curative effects on certain tumors, serious immune-related adverse events limited the clinical application. Therefore, it is urgent to develop new drugs with the same efficacy but fewer side effects than PD-1/PD-L1 inhibitors. In addition, exploring the mechanisms of immune-related adverse events provides a scientific foundation for developing personalized intervention strategies, which is equally important in the research of PD-1/PD-L1 inhibitors. This review discusses the mechanism and immune-related adverse events of several anti-PD-1/PD-L1 monoclonal antibodies, aiming at reminding clinicians of the occurrence of related adverse events while performing anti-tumor therapy. Moreover, this review also points out the possible research direction of PD-1/PD-L1 inhibitors in the future.https://www.chinagp.net/fileup/1007-9572/PDF/yx202101312.pdf|antineoplastic agents, immunological|programmed cell death protein 1|programmed death ligand 1|immunosuppressive agents|monoclonal antibody|adverse event |
| spellingShingle | YANG Leiyi, LIN Sang, XIE Qibing, YIN Geng Current Status of PD-1/PD-L1 Anti-tumor Therapy and Exploration of the Mechanism of Immune-related Adverse Events Zhongguo quanke yixue |antineoplastic agents, immunological|programmed cell death protein 1|programmed death ligand 1|immunosuppressive agents|monoclonal antibody|adverse event |
| title | Current Status of PD-1/PD-L1 Anti-tumor
Therapy and Exploration of the Mechanism of Immune-related Adverse Events |
| title_full | Current Status of PD-1/PD-L1 Anti-tumor
Therapy and Exploration of the Mechanism of Immune-related Adverse Events |
| title_fullStr | Current Status of PD-1/PD-L1 Anti-tumor
Therapy and Exploration of the Mechanism of Immune-related Adverse Events |
| title_full_unstemmed | Current Status of PD-1/PD-L1 Anti-tumor
Therapy and Exploration of the Mechanism of Immune-related Adverse Events |
| title_short | Current Status of PD-1/PD-L1 Anti-tumor
Therapy and Exploration of the Mechanism of Immune-related Adverse Events |
| title_sort | current status of pd 1 pd l1 anti tumor therapy and exploration of the mechanism of immune related adverse events |
| topic | |antineoplastic agents, immunological|programmed cell death protein 1|programmed death ligand 1|immunosuppressive agents|monoclonal antibody|adverse event |
| url | https://www.chinagp.net/fileup/1007-9572/PDF/yx202101312.pdf |
| work_keys_str_mv | AT yangleiyilinsangxieqibingyingeng currentstatusofpd1pdl1antitumortherapyandexplorationofthemechanismofimmunerelatedadverseevents |